| A single-centre, placebo-controlled, cross-over, double blind study of the effects on salivation by increasing doses of physostigmine applied to the labial mucosa of subjects with chronic dry mouth symptoms. A phase II dose-finding study. - Calabarstudien | A single-centre, placebo-controlled, cross-over, double blind study of the effects on salivation by increasing doses of physostigmine applied to the labial mucosa of subjects with chronic dry mouth symptoms. A phase II dose-finding study. - Calabarstudien | EUCTR2005-006017-41-SE |
| The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy | | NCT01121497 |
| A programme to develop a skin patch containing two medicines (physostigmine and hyoscine), study 5: Assessment of blood levels of the two medicines and any associated symptoms in healthy male participants | A two-part study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple applications of the F11/25 transdermal patch formulation of hyoscine and physostigmine in healthy male participants | ISRCTN79173829 |
| A study of the blood levels of physostigmine and hyoscine and associated symptoms following intravenous administration in healthy male and female participants. | A randomised, double-blind, placebo-controlled, crossover, dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of physostigmine salicylate and hyoscine hydrobromide by continuous, intravenous infusion to healthy Caucasian male and female volunteers, given separately and in combination. | ISRCTN78730348 |
| A programme to develop a skin patch containing two medicines (physostigmine and hyoscine), Study 3: Assessment of blood levels of the two medicines and any associated symptoms in healthy male participants wearing four prototype skin patches. | A Two-part Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Applications of Four Transdermal Patch Formulations of Hyoscine and Physostigmine in Healthy Male Participants | ISRCTN16859029 |
| Reduced opioid consumption through continuous infusion of physostigmine in addition to postoperative patient-controlled analgesia for nephrectomy | PHANOS (PHysostigmine-enHAnced Opioid analgeSia) study - PHANOS2012 | EUCTR2012-000130-19-AT |
| A programme to develop a skin patch containing two medicines (physostigmine and hyoscine) - study 2: Assessment of blood levels of the two medicines and any associated symptoms in healthy male participants wearing four prototype skin patches | A Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Four Transdermal Patch Formulations (F4-F7) of Hyoscine and Physostigmine in Healthy Male Subjects | ISRCTN29062676 |
| Reduzierter Opioidverbrauch durch Physostigmin als Dauertropf zur postoperativen PCA – PHANOS (PHysostigmine-enhANced Opioid analgeSia).prospektive, doppelblinde, randomisierte, placebokontrollierte Phase III Studie | Reduzierter Opioidverbrauch durch Physostigmin als Dauertropf zur postoperativen PCA – PHANOS (PHysostigmine-enhANced Opioid analgeSia).prospektive, doppelblinde, randomisierte, placebokontrollierte Phase III Studie | EUCTR2010-021901-19-AT |
| Physostigmine After General Anesthesia | The Use of Physostigmine in Elderly Patients in the Postoperative Recovery-phase After General Anesthesia | NCT00850850 |
| A programme to develop a skin patch containing two medicines (physostigmine and hyoscine), Study 6: Assessment of blood levels of the two medicines and any associated symptoms in healthy female participants. | A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single application (one or two dose levels) and multiple applications (one dose level) of the transdermal patch formulations of physostigmine and hyoscine in healthy female subjects | ISRCTN15358284 |
| A programme to develop a skin patch containing two medicines (physostigmine and hyoscine), Study 8: Assessment of effects of consecutive 24-hour applications of patches for 21 days on the blood levels of the two medicines and any associated symptoms in healthy male and female participants | A double-blind investigation of the effects of daily applications of the physostigmine and hyoscine transdermal patch (NAPS2 F11/21) with an armband on the pharmacokinetic (PK), pharmacodynamic (PD) and safety profiles over a 21-day period in healthy male and female Caucasian subjects | ISRCTN62968791 |
| A programme to develop a skin patch containing two medicines (physostigmine and hyoscine), Study 1: Assessment of blood levels of the two medicines and any associated symptoms in healthy male participants wearing prototype skin patches | A randomised, double-blind, three-way crossover study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability after single applications of three transdermal patch formulations of physostigmine and hyoscine in healthy males | ISRCTN21827000 |
| Efficacy and tolerability of physostigmine salicylate for treatment of post-operative delirium after aortocoronary-bypass operation (ACVB): a prospective, double-blind, placebo-controlled, two parallel-groups, phase III study | | ISRCTN33122761 |
| A study of a skin patch containing two medicines (physostigmine and hyoscine) in healthy male participants to assess the blood levels of the two medicines and any associated symptoms. | An open, replicate, two-period, single and multiple-dose, pharmacokinetic and tolerability study of the PHP (150 g/m2) transdermal patch containing physostigmine and hyoscine in healthy, adult Caucasian males. | ISRCTN10362655 |
| Perioperative physostigmine prophylaxis for liver resection patients at postoperative risk for confusion, lack of concentration and orientation and postoperative cognitive dysfunction. | Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dysfunctionPerioperative Gabe von Physostigmin bei Leberteilresktion zur Prophylaxe von Delir und postoperativem kognitivem Defizit - PHYDELIO | EUCTR2008-007237-47-DE |
| Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome | A Randomized Trial Comparing Physostigmine vs Lorazepam for Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome | NCT03090620 |
| A programme to develop a skin patch containing two medicines (physostigmine and hyoscine), Study 7: Assessment of effects of an armband covering the skin patch on the blood levels of the two medicines and any associated symptoms in healthy male participants | An investigation of the effects of an armband applied over the F11/21 physostigmine and hyoscine transdermal patch on pharmacokinetic, pharmacodynamic and safety profiles in healthy male subjects | ISRCTN13607674 |
| A programme to develop a skin patch containing two medicines (physostigmine and hyoscine), study 4: Assessment of blood levels of the two medicines and any associated symptoms in healthy male participants with Fitzpatrick Grade 5 skin pigmentation. | A Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Application of a Transdermal Patch Formulation of Hyoscine and Physostigmine in Healthy Male Subjects with Pigmented Skin of Grade 5 on the Fitzpatrick Skin Scale | ISRCTN73285902 |
| Anticholium® Per Se | Anticholium® Per Se a Randomized, Double-blind, Placebo-controlled, Monocentric Trial on the Adjunctive Use of Physostigmine Salicylate (Anticholium®) in Perioperative Sepsis and Septic Shock | NCT03013322 |
